TITLE

Mieloma múltiple

AUTHOR(S)
Velázquez, Joel Omar Reyes; Loera Torres, C. D. Luis Enrique
PUB. DATE
October 2008
SOURCE
Medicina Oral (16656024);2008, Vol. 10 Issue 4, p108
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Multiple myeloma is a malignant disease that produce bone loss, acute and inabilitant pain, anemia, pathologic fractures, hypercalcemia, kidney damage and recurrent infections. Diagnosis is based on plasmatic cells counting-up, plasmocitoma biopsy and existence of secondary clinical sympthoms of several injuried vital organs. The treatment has as goal to prevent the bone loss, to keep his advance and reparation of caused damage, actually, thalidomide and proteasomma immunomodulator drugs and more recently biphosphonate are used.
ACCESSION #
43662565

 

Related Articles

  • Alendronat Kullanımına BaÄŸlı Oral Ãœlserler. Cinemre, Hakan; Bilir, Cemil; Gökosmanoğlu, Feyzi; Aytuğ, Necip Ö. // Romatizma/Rheumatism;mar2008, Vol. 23 Issue 1, p35 

    Bisphosphonates are the drugs which modulate bone turnover and reduce bone reabsorbsion. Hence, they are used in postmenopausal osteoporosis , multiple myeloma or osteolisis associated with malign cancer. The rare complications are appearing more often now because of their wide use in...

  • Lenalidomide: A Review of Its Continuous Use in Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Stem-Cell Transplantation. McCormack, Paul // Drugs & Aging;May2015, Vol. 32 Issue 5, p409 

    Lenalidomide (Revlimid) is a second-generation immunomodulatory drug structurally related to thalidomide, with improved efficacy and tolerability, for which the label in the EU was recently expanded to include continuous therapy in patients with previously untreated multiple myeloma not eligible...

  • Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma. Gupta, Vikas A.; Nooka, Ajay K.; Lonial, Sagar; Boise, Lawrence H. // Blood & Lymphatic Cancer: Targets & Therapy;May2013, Vol. 3, p41 

    Treatment of refractory and/or relapsed multiple myeloma has been a challenging problem for over 20 years. However, we have made significant progress addressing this disease with the use of bortezomib, the first in class proteasome inhibitor, and the immunomodulatory agents, thalidomide and...

  • Myelosuppression Associated With Novel Therapies in Patients With Multiple Myeloma: Consensus Statement of the IMF Nurse Leadership Board. Miceli, Teresa; Colson, Kathleen; Gavino, Maria; Lilleby, Kathy // Clinical Journal of Oncology Nursing;Jun2008 Supplement, Vol. 12, p13 

    Novel therapies for multiple myeloma include the immunomodulatory drugs lenalidomide and thalidomide and the proteasome inhibitor bortezomib, which have increased response rates and survival times. However, the agents can cause myelosuppression, which, if not managed effectively, can be life...

  • Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT. Pitini, V; Arrigo, C; Aloi, G; Micali, C; La Gattuta, G // Bone Marrow Transplantation;Jun2003, Vol. 31 Issue 11, p1065 

    Bone Marrow Transplantation (2003) 31, 1065. doi:10.1038/sj.bmt.1704079

  • Advances in Oral Therapy in the Treatment of Multiple Myeloma. Doss, Deborah S. // Clinical Journal of Oncology Nursing;Aug2006, Vol. 10 Issue 4, p514 

    Conventional IV chemotherapy regimens used for induction chemotherapy or salvage therapy in the treatment of multiple myeloma (MM) are cumbersome, with a negative impact on patient quality of life. A number of new oral drugs, including immunomodulatory agents such as thalidomide and...

  • Reply to the letter by V Pitini. Alam, A R // Bone Marrow Transplantation;Jun2003, Vol. 31 Issue 11, p1067 

    Bone Marrow Transplantation (2003) 31, 1067-1067. doi:10.1038/sj.bmt.1704080

  • Multiple Myeloma Match-Up: A Test in Managing the Myeloma Patient With Comorbid Conditions. Baker, Amanda // ONS Connect;Aug2012 Spotlight on Symposia, p11 

    The article discusses a symposium held on May 4, 2012 at the Hilton New Orleans Riverside Hotel in Louisiana on the tests of comorbid conditions for managing the patients suffering from multiple myeloma. Topics include bone complications, peripheral neuropathy (PN) and venous thromboembolism...

  • Multiple Myeloma: The Patient's Journey Through Survivorship. Nicoletti, Amy // ONS Connect;Aug2012 Spotlight on Symposia, p3 

    The article discusses a symposium held at the Hilton New Orleans Riverside Hotel in Louisiana on May 3, 2012, on a journey for the survivorship of the patients suffering from multiple myeloma (MM). Topics include presentation of the patients, renal complications and bone lesions. The symposium...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics